Infusion reactions, hypersensitivity and extravasation
Reactions around the moment a drug is given: chills, fever or breathlessness from antibodies (infusion reactions), true allergy (hypersensitivity, rarely anaphylaxis), and leakage of a damaging drug into tissue around the vein (extravasation).
Infusion reactions are common with first doses of rituximab, cetuximab, daratumumab and other antibodies (cytokine release from target cells) and with taxanes and platinum (hypersensitivity, rising with cumulative carboplatin exposure); premedication with antihistamines, steroids and paracetamol, slow initial rates and subcutaneous formulations (rituximab, daratumumab, atezolizumab, pembrolizumab) reduce them. Anaphylaxis to asparaginase or platinum leads to switching agents or desensitisation. Extravasation of vesicants (anthracyclines, vinca alkaloids) causes tissue necrosis and is why central venous access is used; dexrazoxane treats anthracycline extravasation. These are distinct from cytokine release syndrome after T-cell engagers, though mechanistically related.
Pages like this
not linked directly; found by shared links- TermR-CHOP (lymphoma chemoimmunotherapy)
- TermHypogammaglobulinaemia and infection risk after B-cell therapies
Shares Rituximab, Cytokine release syndrome (CRS).
- PathwayComplement in cancer
Shares Rituximab, Daratumumab, Cytokine release syndrome (CRS).
- PathwayNK-cell recognition: missing self & stress ligands
Shares Rituximab, Cetuximab, Daratumumab.
- Key paperCARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy
- TermADCC (antibody-dependent cellular cytotoxicity)
Shares Rituximab, Daratumumab.
- CancerCutaneous squamous cell carcinoma
Shares Cetuximab, Carboplatin.